Previous 10 | Next 10 |
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023 at 9:30 a.m. ET. A live audio webcast of the pres...
Summary Despite a weak outlook for 2023 due to macro factors, IQV's revenue and EPS for Q4 2022 were better than expected. IQV is facing wage inflation pressures due to recruiting highly sought-after talent. I am recommending to go long on the basis of expected margin expansion (dri...
IQVIA (NYSE:IQV) has published its 2022 Environmental, Social and Governance (ESG) Report. The annual report provides a detailed account of the organization’s focus on reducing its environmental impact and commitment to accelerating positive outcomes for public health and patients. ...
For investors looking to double their money, look for healthcare stocks that are consistently increasing revenue and earnings per share (EPS). Cigna Group (NYSE: CI) , Danaher (NYSE: DHR) , and IQVIA Holdings (NYSE: IQV) all have managed to generate double-digit (o...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Healthcare stocks are hot right now. The S&P 500 Health Care index has gained 3% over the last 12 months versus the 8% decline of the broader S&P 500 benchmark index . Reasons that healthcare stocks have outper...
IQVIA Holdings ( NYSE: IQV ) has traded as much as 3% down in Friday trading after releasing 2023 guidance figures after Thursday's closing bell that came in below consensus estimates. In 2023, the analytics and clinical research services provider is projecting revenue of between ...
IQVIA Holdings (IQV) Q4 2022 Earnings Conference Call February 10, 2023 9:00 a.m. ET Company Participants Nick Childs - Senior Vice President, Investor Relations and Treasurer Ari Bousbib - Chairman and Chief Executive Officer Ron Bruehlman - Executive Vice President a...
IQVIA press release ( NYSE: IQV ): Q4 Non-GAAP EPS of $2.78 beats by $0.02 . Revenue of $3.74B (+2.7% Y/Y) beats by $30M . For FY2023, the company expects revenue to be between $15.15B and $15.4B vs. consensus of $15.41B; Adjusted EBITDA to be between $.625B and $3.6...
Revenue of $3,739 million for the fourth quarter, $14,410 million for the full year GAAP Net Income of $227 million for the fourth quarter, $1,091 million for the full year Adjusted EBITDA of $920 million for the fourth quarter, $3,346 million for the full year GAAP Dilute...
IQVIA ™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been named to FORTUNE magazine’s “World’s Most Admired Companies” list for the sixth consecutive year. ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 10:00:13 ET Jailendra Singh from Truist Financial issued a price target of $300.00 for IQV on 2024-07-23 09:26:00. The adjusted price target was set to $300.00. At the time of the announcement, IQV was trading at $240.265. The overall price target consensus is...
2024-07-23 10:00:11 ET Elizabeth Anderson from Evercore ISI issued a price target of $270.00 for IQV on 2024-07-23 08:59:00. The adjusted price target was set to $270.00. At the time of the announcement, IQV was trading at $239.5. The overall price target consensus is at...
2024-07-23 07:00:06 ET Luke Sergott from Barclays issued a price target of $275.00 for IQV on 2024-07-23 05:25:00. The adjusted price target was set to $275.00. At the time of the announcement, IQV was trading at $245.23. The overall price target consensus is at $273.93 ...